Australian Dry Eye

Click here to edit subtitle

News

view:  full / summary

Can cannabis succeed where other compounds have failed

Posted by australiandryeye on November 20, 2017 at 8:15 PM Comments comments (0)

Cannabinoids could have potential in a novel topical drug delivery vehicle to treat neuropathic dry eye pain.


The disconnect between signs and symptoms in dry eye disease is an intriguing clinical problem. Although we know quite a lot about the etiology of dry eye, the ideal structure of the tear film and how to diagnose and treat dry eye disease, there are still some patients who do not respond to treatment or who present complaining of severe symptom...

Read Full Post »

VIDEO: Consider neuropathic pain in stubborn dry eye

Posted by australiandryeye on November 2, 2017 at 6:20 PM Comments comments (0)

CHICAGO – Rich Mangan, OD, and Scott Hauswirth, OD, discussed a new area of ocular surface disease involving chronic, or neuropathic, pain.


Hauswirth said to consider this condition in dry eye patients who experience light sensitivity and those with symptoms that tend to never go away despite treatment.


Read Full Post »

The DED Pipeline Isn't Drying Up

Posted by australiandryeye on October 31, 2017 at 10:35 PM Comments comments (0)

The possible causes are many and prescription treatments few, but new and potential dry-eye therapeutics keep coming.


The update reflects the most current understanding of dry-eye disease as a disruption in homeostasis and emphasizes the importance of hyperosmolarity in dry-eye tears and the role of inflammation in DED. Inflammatory mediators are frequent therapeutic targets. As things stand, Restasis and Xiidra (Allergan and Shire, respectively) a...

Read Full Post »

RegeneRx JV Announces Results of ARISE-2 Dry Eye Trial

Posted by australiandryeye on October 31, 2017 at 8:20 PM Comments comments (0)

ROCKVILLE, Md., Oct. 31, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the results of its phase 3 dry eye trial sponsored by its U.S. joint venture, ReGenTree, LLC. The ARISE-2 trial investigated the safety and efficacy of RGN-259 compared to placebo for the treatment of the signs and symptoms of dry eye syndrome in 601 patient...

Read Full Post »

Mitotech: a (very) different approach to treating Dry Eye

Posted by australiandryeye on October 30, 2017 at 9:50 PM Comments comments (0)

Approximately 16 million Americans have been told by their doctor that they have Dry Eye Disease – the itchy, uncomfortable and inconvenient condition that remains the number one reason people go see an ophthalmologist.


People with Dry Eye Disease either produce poor quality tears or do not produce a sufficient amount of tears to nourish and lubricate the front of the cornea, leading to eyes that feel chronically irritated, gritty, red, and scratchy.

 

Read Full Post »

FDA allows Cambium dry eye study to proceed

Posted by australiandryeye on October 26, 2017 at 2:20 AM Comments comments (0)

The FDA notified Cambium Medical Technologies that its phase 1 study of topical fibrinogen-depleted human platelet lysate for treatment of dry eye disease can proceed, according to a company press release.


Cambium filed an Investigational New Drug Application in late August for this potential early phase efficacy trial.


Experts stage prescription therapies for dry eye


“We are delighted this study is about to start,” Terence Wal...

Read Full Post »

Mitotech S.A announced positive data from their recent Dry Eye study.

Posted by australiandryeye on October 24, 2017 at 7:00 PM Comments comments (0)

LUXEMBOURG (PRWEB) OCTOBER 24, 2017

Mitotech S.A, a Luxembourg based biotechnology company marketing its Dry Eye drug Visomitin in Russia, announced positive data from their recent study involving a novel Dry Eye model. Dry Eye Disease has been associated with several biological factors including inflammation, decrease in tear quality and corneal damage. Only two active treatments have been approved by the FDA for this disease, both acting as anti-inflammatory agents. Currently there is...

Read Full Post »

Huons to proceed with phase 3 clinical trials for dry eye treatment

Posted by australiandryeye on October 24, 2017 at 7:00 PM Comments comments (0)

Huons said Tuesday it has received approval from the Ministry of Food and Drug Safety to go ahead with domestic phase 3 clinical trials for HU007, a nanocomposite eye drops used for treating dry eye syndrome.


Dry eye syndrome is a common eye condition in which the eye surface gets damaged due to insufficient tear production or excessive tear evaporation. The number of patients suffering from the disorder is on the rise because of the increase of computers, smart devices, air...

Read Full Post »

Imprimis spins out dry eye disease drugs to create biotech

Posted by australiandryeye on October 24, 2017 at 6:55 PM Comments comments (0)

Imprimis Pharmaceuticals has created subsidiary focused on dry eye disease. The offshoot, Surface Pharmaceuticals, plans to develop three formulations in ophthalmology indications fought over by companies including Allergan and Shire.


San Diego, California-based Imprimis is a pharmacy that provides proprietary compounded formulations. This line of work has led Imprimis to identify compounded drugs it thinks have a shot at winning approval under the FDA’s 505(b)(2) path...

Read Full Post »

Biotech startup Azura Ophthalmics raises $20 million to cure dry eye disease

Posted by australiandryeye on October 22, 2017 at 11:30 PM Comments comments (0)

Australian and Israeli-based biotech startup Azura Ophthalmics has raised $US16 million ($20 million) to fund treatments for a disease many in the startup world may not be aware of, but which affects 300 million people worldwide: meibomian gland dysfunction, a leading cause of dry eye disease.


Meibomian gland dysfunction (MGD) is responsible for at least 70 percent of dry eye cases, according to Azura Opthalmics chief executive Marc Gleeson, who says there are currently no p...

Read Full Post »

Help from the Stomach for Dry Eye

Posted by australiandryeye on August 5, 2017 at 4:30 AM Comments comments (0)


After a long day of working at the computer, scratchy contact lenses are not only painful, over longer periods of time they can also damage ocular tissue. Relief may be in sight from a natural mucus component referred to as a mucin. A team from the Technical University of Munich (TUM) has now succeeded in demonstrating that contact lenses coated with purified porcine gastric mucin do not cause damage to the eye anymore.

 

Mucins are molecules capable of binding lo...

Read Full Post »

Dry Eyes Deserve Attention

Posted by australiandryeye on August 5, 2017 at 4:25 AM Comments comments (0)


Putting carboxymethylcellulose sodium in one’s eyes two, three or more times a day may not sound like a great experience. But I can assure you that it can be. Drops of this chemical, called a topical lubricant, help to keep my eyes from burning, avoiding bright lights, becoming red and itchy, and generally feeling miserable.

 

Like tens of millions of Americans, especially women older than 50, I have dry eye disease, medically known as keratoconjunctivitis s...

Read Full Post »

New dry eye drug is first that aims to treat cause, rather than symptoms

Posted by australiandryeye on July 13, 2017 at 6:25 AM Comments comments (0)

University of Virginia Health System researchers have developed a potential therapeutic treatment for dry eye, with human testing to start in March. The drug differs from other treatments of dry eye in that it aims to treat the cause of dry eye instead of masking the symptoms.


The drug, trademarked as "Lacripep," is a topical eye drop that functions differently from conventional approaches. Rather than seeking to suppress inflammation – an approach with mixed results &...

Read Full Post »

Sylentis Initiates a Phase III Study for the Treatment of Dry Eye Syndrome

Posted by australiandryeye on June 9, 2017 at 4:05 AM Comments comments (0)

The pharmaceutical Company Sylentis (PharmaMar Group) has announced the start of the first Phase III study, HELIX, with the investigational new drug, SYL1001 for the indication of dry eye syndrome. The Company has agreed with the U.S. Food and Drug Administration (FDA) on plans for the Phase III clinical program, which is designed to support the submission of a New Drug Application (NDA). The Company has received final, End-of-Phase II meeting minutes from the FDA.


(Log...

Read Full Post »

Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial

Posted by australiandryeye on June 9, 2017 at 4:00 AM Comments comments (0)

LEXINGTON, Mass., June 6, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced that it has enrolled the first patient into a Phase 2a clinical trial of topical ocular ADX-102 for the treatment of Dry Eye Disease (DED).


 

"Dry Eye Disease is a common ocular inflammatory condition with hig...

Read Full Post »

Lamellar Biomedical Recruits First Patients Into Clinical Study Assessing LAMELLEYE for Treatment of Dry Eye Disease

Posted by australiandryeye on June 9, 2017 at 4:00 AM Comments comments (0)


Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical and pharmaceutical products, based on its LAMELLASOME™ technology, announces the recruitment of the first patients in a clinical study assessing LAMELLEYE for the treatment of moderate to severe Dry Eye Disease (DED). Moderate to severe DED is a significant clinical problem for which there are no effective treatments that tackle the underlying cause.



LAME...

Read Full Post »

New Dry Eye Web Store Coming Soon!

Posted by australiandryeye on June 9, 2017 at 12:20 AM Comments comments (1)

AustralianDryEye is currently in the process of developing new webstore to retail products specifically for the needs of dry eye patients.


Stayed tuned for updates.

RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017

Posted by australiandryeye on May 14, 2017 at 6:50 AM Comments comments (0)

ROCKVILLE, Md., May 9, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced that its joint venture, ReGenTree LLC, presented the results of its ARISE-1 Phase 2b/3 dry eye clinical trial in a poster session to physicians, scientists, and analysts today at the 2017 ARVO meeting in Baltimore, Maryland.


As previously report...

Read Full Post »

Shire pays $20M for Parions midstage dry eye drug

Posted by australiandryeye on May 13, 2017 at 3:35 AM Comments comments (0)

Shire will pay $20 million upfront, with a potential $535 million biobucks if all goes according to plan, for Parion Sciences’ dry eye candidate P-321 as it looks to boost its ophthalmology pipeline.


The deal sees Shire gain exclusive worldwide rights to develop and commercialize P-321, where it will also lead development. The biopharma added that Parion will have “an opportunity to co-fund” work on the medication.

 

P-321 works as an epith...

Read Full Post »

Rss_feed